Paras Healthcare Ltd. has revived plans for an initial public offering and hired three banks for a share sale that could raise as much as $200 million, according to people familiar with the matter. The company, a key player in India’s pharmaceutical sector, aims to capitalize on favorable market conditions after a previous, unspecified attempt. Paras Healthcare seeks to use the funds to fuel expansion and strategic initiatives, signaling confidence in its growth trajectory.

The involvement of three investment banks indicates a structured approach to the IPO, though specifics about the banks’ identities remain undisclosed. This move aligns with broader trends of renewed investor interest in India’s healthcare sector, which has seen increased activity amid global demand for pharmaceutical innovations. Analysts suggest the $200 million target reflects a significant financial commitment, potentially positioning the company as a major stakeholder in the country’s evolving investment landscape.

While the source does not detail the IPO’s timeline or final terms, the revival of the offering highlights the sector’s resilience and the company’s strategic focus on long-term growth. Investors may view this as a vote of confidence in Paras Healthcare’s ability to navigate competitive markets and deliver returns.

The India IPO market, which has seen fluctuating activity in recent years, could benefit from this development, as it may attract more institutional participation. For Paras Healthcare, the successful execution of the IPO would not only strengthen its financial position but also enhance its visibility among global investors, reinforcing its role in the pharmaceutical industry.